Table 5.
HR for combined endpoint of all-cause mortality and ESRD among people with CKD
| Clinical Characteristic | Unadjusted |
Adjusted |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Total leukocyte count increase > 11.5 K/μl | 1.63 | (1.16, 2.28) | <0.01 | 1.15 | (0.80, 1.67) | >0.1 |
| Absolute granulocyte count increase > 8.6 K/μl | 1.7 | (1.20, 2.40) | <0.01 | 1.18 | (0.82, 1.71) | >0.1 |
| Absolute eosinophil count increase > 0.45 K/μl | 2.16 | (1.54, 3.03) | <0.001 | 1.49 | (1.02, 2.17) | 0.04 |
| Granulocyte (%) increase > 70% | 2.99 | (2.01, 4.44) | <0.001 | 1.75 | (1.14, 2.68) | 0.01 |
| Lymphocyte (%) decrease < 18% | 1.52 | (1.05, 2.21) | 0.03 | 0.91 | (0.61, 1.36) | >0.1 |
| Monocyte (%) increase > 11% | 2.93 | (2.01, 4.27) | <0.001 | 1.76 | (1.17, 2.64) | <0.01 |
| Eosinophil (%) increase > 3% | 1.94 | (1.41, 2.67) | <0.001 | 1.58 | (1.13, 2.22) | <0.01 |
| Basophil (%) increase > 2% | 1.38 | (0.98, 1.96) | 0.07 | 1.42 | (0.98, 2.06) | 0.06 |
Multivariate adjusted for age, gender, race, diabetes, smoking, ACEI or ARB use, statin use, BP medication use, baseline CKD stage, and baseline log urine protein/creatinine. HR, hazard ratio; CI, confidence interval.